Introduction
Company Overview
Speclipse, Inc. has developed a transformative, patented technology for real-time, non-invasive, in-vivo cancer diagnosis utilizing laser spectroscopy and machining learning algorithms.
Clinical trials in the United States, Australia, and South Korea have shown a skin-cancer diagnostic accuracy rate of greater than 90%, higher than any other competing technologies that have attempted to achieve a similar clinical outcome. Diagnostic tools presently used by physicians such as dermascopes or confocal microscopes, provide 60-70% accuracy, far below that of Spectra-Scope®.
Speclispe, Inc. has acquired ISO134485 certification for its manufacturing facility, and Specta-Scope® is on-track, expected to obtain CE mark and TGA approval in early 2019.
About Us
Speclipse was founded by three Stanford University graduates and a dermatologist in November 2015, and currently has offices in Silicon Valley, California and South Korea. Speclipse’s technology was first developed in conjunction with a South Korean national lab, KIMM (Korea Institute of Machinery and Materials), and Seoul National University Hospital. Speclipse raised $3M in November 2016 and is planning for commercial launch of their Spectra-Scope® product in 2019.
Spectra-Scope
Core Technology
Speclipse's core diagnostic technology based on Laser Induced Plasma Spectroscopy (LIPS) and deep learning algorithms resides in "Spectra-Scope". It can be used by medical or cosmetic clinics who do not have existing laser equipment, or who prefer a small, portable stand-alone device for real-time diagnosis.
Due to the instantaneous nature and high-accuracy results provided by this technology, it is valuable for use in pathology labs for diagnosing biopsy samples, and beneficial for real-time diagnosis during oncological surgeries as well.
Besides its outstanding clinical benefit, Spectra-Scope’s® size and portability make it uniquely qualified to address the unmet need for a technology which provides diagnostic accuracy and real-time results, with a cost-effective and minimal footprint.
Team
Core Members
Chief Executive Officer
Sung Hyun Pyun
-
Former Senior Engineer, KIMM
-
Former Consultant, The Boston Consulting Group
-
M.S. / Ph.D. in ME, Stanford University (Advanced Laser Diagnostics and Shock Tube Lab)
-
B.S. in ME, KAIST
Chief Technology Officer
Wanki Min
-
M.S. in ME, Stanford University (Advanced Laser Diagnostics and Shock Tube Lab)
-
B.S in ME, Seoul National University
-
Extensive experiences on laser sensor development
Chief AI Officer
Minsan Ko, PhD
-
Assistant professor of ICT dept., Hanyang University
-
Former data scientist at AIRI
-
Former data scientist at Samsung
-
M.S., Ph.D. in Computer Science, KAIST
Chief Medical Officer
Boncheol Goo
-
Head, Naeum Dermatology and Aesthetic Clinic
-
Medical Director, Lutronic, Inc.
-
M.D., Ph.D. in Yonsei Univ.
VP of US Business
Hyukmin Kwon
-
Former Lead Engineer, 1366 Technologies, Inc.
-
Ph.D. in ME, Massachusette Institute of Technology (Varanasi Group)
-
M.S. in ME, Stanford University (Microfluidics Lab)
-
B.S in ME, Seoul National University
Advisory Board
Medical Advisor
Chang Huh
-
Professor of Dermatology, SNU Hospital
-
M.D., Ph.D. in SNU
PD/FDA Process Advisor
Joe Mooney
-
Project Manger at Johnson & Johnson
-
20+ year of FDA Class II device development
-
WPI M.S.
Investment Advisor
Jin Lee
-
President of Silicon Valley at LS Corp.
-
Former CTO at GE Healthcare
-
Ph.D. in ME, Stanford University
Contact
Korea Office
Markcity Orange #502
123, Unjung-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea
US Office
310 De Guigne Dr
Sunnyvale, California 94085 USA
For any inquiries,
Please call or e-mail us:
+82-31-698-2269